Similar gene expression signatures and similar benefits from menin inhibition have been shown in preclinical studies for NPM1-mutant AML [154,155], NUP98-rearranged AML [156], and UBTF mutated AML [157,158]. This evidence concerns the gene NPM1 and acute myeloid leukemia.